Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US35104E1001
Share Class Description:
FDMT: Ordinary SharesTotal Employee Number:
196Description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 19.04 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.8 | |||||
Beneish M-Score | 3418.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 147.5 | |||||
3-Year EBITDA Growth Rate | 7.2 | |||||
3-Year EPS without NRI Growth Rate | 10 | |||||
3-Year FCF Growth Rate | 14.6 | |||||
3-Year Book Growth Rate | 7.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -15.65 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.92 | |||||
9-Day RSI | 73.17 | |||||
14-Day RSI | 66.97 | |||||
3-1 Month Momentum % | -14.44 | |||||
6-1 Month Momentum % | 9.28 | |||||
12-1 Month Momentum % | 114 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.34 | |||||
Quick Ratio | 9.34 | |||||
Cash Ratio | 9.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.9 | |||||
Shareholder Yield % | -1.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -203.47 | |||||
Net Margin % | -182.34 | |||||
EBITDA Margin % | -194.49 | |||||
FCF Margin % | -146.59 | |||||
OCF Margin % | -146.7 | |||||
ROE % | -36.29 | |||||
ROA % | -32.27 | |||||
ROIC % | -118.52 | |||||
3-Year ROIIC % | -43.19 | |||||
ROC (Joel Greenblatt) % | -512.16 | |||||
ROCE % | -38.92 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.42 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | -1.31 | |||||
EV-to-EBITDA | -1.38 | |||||
EV-to-Revenue | 2.68 | |||||
EV-to-Forward-Revenue | 31.25 | |||||
EV-to-FCF | -1.82 | |||||
Price-to-GF-Value | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.76 | |||||
| Price-to-Net-Cash | 1.84 | |||||
Earnings Yield (Greenblatt) % | -76.34 | |||||
FCF Yield % | -21.33 |
4D Molecular Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4D Molecular Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 45 days | ||
| General meeting for 2026 | 2026-06-17 10:30 | 8.67 (-5.76%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 14:00 | 8.64 (-2.26%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 9.27 (-3.64%) | ||
| Guidance call for 2026 | 2026-05-19 14:35 | 8.37 (-8.18%) | ||
| Guidance call for 2026 | 2026-05-13 13:40 | 10.34 (-4.17%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 10.42 (+6.76%) | ||
| RBC Capital Markets Global Ophthalmology Conference | 2026-03-24 15:45 | 9.23 (+4.89%) | ||
| Leerink Partners Mountain Meeting | 2026-03-22 | 8.61 (-0.23%) |
Show
Entries
Guru Commentaries on NAS:FDMT
No articles.
Press Release
Articles on 4D Molecular Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers